Comvita FY26 slides: return to profit, North America sales double

Comvita reported FY26 net profit after tax of NZD 7.7M (vs a prior-year loss) as revenue rose 10.7% to NZD 213.0M, with normalized EBIT of NZD 16.4M beating guidance of NZD 15.5M by ~5.8%. The turnaround included a $43.0M swing in operating performance (operating loss of NZD 29.0M to operating profit of NZD 14.0M), gross margin expanding 3.1pp to 53.9%, and a balance-sheet shift from net debt of NZD 62.4M to net cash of NZD 0.5M after refinancing. Inventory fell from NZD 89.0M to NZD 79.9M and operating cash flow rose to NZD 40.3M (+NZD 6.1M), while North America sales more than doubled to NZD 58.7M (though contribution margin declined). Stock traded at $0.80, up 1.27% near the 52-week high, but management did not provide FY27 guidance due to limited visibility.

Analysis

The key market implication is not the earnings bounce itself, but the removal of equity-risk overhang. A net-cash balance sheet plus covenant headroom converts the story from “survival/repair” to “cash compounding,” which usually supports a lower discount rate and a better rerating multiple for small-cap consumer names. That said, the quality of the recovery is still uneven: the earnings lift was helped by working-capital release and manufacturing leverage, so the market should not extrapolate margin expansion linearly once inventory normalization is complete.

Competitive dynamics look better in regions where premium branding can still defend price, but North America’s rapid volume growth also signals a channel mix that can commoditize the category faster than investors expect. Lower-UMF and online channels tend to attract private-label and discount competitors first, so the second-order risk is that a share-gain strategy forces contribution margins down before scale benefits arrive. In Greater China, any continued softness would matter more for valuation than headline revenue because it pressures the business mix that traditionally supported higher margin and turns the turnaround into a low-quality growth story.

Near term, the trade is driven by FY27 crop, sell-through, and whether the company can sustain cash conversion without another one-off release. Over 6-18 months, the real catalyst is a credible dividend framework or evidence that premium innovation can raise contribution margin in North America without sacrificing growth. The contrarian view is that the move may be partially overdone: investors may be pricing a durable reset before seeing proof that demand, not just inventory cleanup, is doing the heavy lifting.

Key Decisions for Investors

• Initiate a small tactical long CVNZF only on pullbacks, not strength; thesis is balance-sheet de-risking and potential multiple expansion, but keep size modest given small-cap liquidity and the absence of formal FY27 guidance.
• Set a hard thesis check on the next trading update: if gross margin drops back below ~51% or operating cash flow fails to stay above FY25 levels, treat the turnaround as mostly non-recurring and reduce exposure.
• Watch North America contribution margin as the key falsifier; if growth stays above market but contribution remains sub-10%, the market is likely to re-rate the stock downward as a volume-at-any-cost story.
• No options expression unless liquidity improves; the cleaner edge is event-driven equity ownership into the next crop/sell-through update, where a weak harvest or destocking would be the first catalyst to reverse sentiment.
• If the stock approaches or fails to hold recent highs without a margin beat, take profits into strength; the near-term rerating has already priced some balance-sheet repair, and the next leg requires proof of durable operating leverage.